The US General Medicines segment
Allergan’s (AGN) US General Medicines business includes products from therapeutic areas including the central nervous system, gastroenterology, women’s health, anti-infectives, and established brands franchises.
The US General Medicines segment reported revenues of $1.35 billion in 1Q17, which marked a 7.4% decline from its $1.45 billion in 1Q16. The decrease in revenues was mainly due to lower sales of Namenda and Asacol. However, the strong sales of Linzess, Lo Loestrin, and new products Viberzi, and Vraylar partially offset the decline.
The performances of the franchises in Allergan’s US General Medicines segment for 1Q17 were as follows:
- The CNS (central nervous system) franchise includes the Alzheimer’s products and reported revenues of $309.1 million for 1Q17—a 3.9% decline from 1Q16….